Ali H A, el-Yazigi A, Sieck J O, Ali M A, Raines D A, Saour J, Ernst P, Khan B, Døssing M
Department of Medicine, King Faisal Specialist Hospital and Research Centre Riyadh, Saudi Arabia.
J Hepatol. 1995 Jan;22(1):17-21. doi: 10.1016/0168-8278(95)80254-1.
BACKGROUND/AIMS: Our aim was to study whether chronic hepatitis C affects the three metabolic pathways of the model drug antipyrine differently.
We measured antipyrine clearance from saliva as well as urinary excretion of its main metabolites 4-hydroxy-antipyrine, 3-hydroxy-methyl-antipyrine, and nor-antipyrine in 24 patients with chronic hepatitis C and in 21 healthy control subjects. Due to incomplete urine collection, 12 liver patients and three controls were excluded.
Antipyrine clearance (mean +/- SD) was significantly lower in patients with chronic hepatitis C, 1.2 +/- 0.7 l.h-1 (n = 12), than in controls (n = 18), 2.2 +/- 1.0 l.h-1 (p = 0.006). The urinary excretion of each of the metabolites was depressed to an equal extent in liver patients. The severity of the liver disease, as assessed by Child Pugh score, serum albumin and bilirubin, correlated significantly with antipyrine clearance and urinary excretion of the metabolite 3-hydroxy-methyl-antipyrine. The hepatitis activity index (Knodell) correlated with 3-hydroxy-methyl-antipyrine and 4-hydroxy-antipyrine, only.
Moderate-severe chronic hepatitis C does not seem to depress the three main metabolic pathways of antipyrine differently.
背景/目的：我们的目的是研究慢性丙型肝炎是否对模型药物安替比林的三种代谢途径产生不同影响。
我们测量了24例慢性丙型肝炎患者和21名健康对照者唾液中安替比林的清除率及其主要代谢产物4-羟基安替比林、3-羟基甲基安替比林和去甲安替比林的尿排泄量。由于尿液收集不全，排除了12例肝病患者和3名对照者。
慢性丙型肝炎患者（n = 12）的安替比林清除率（均值±标准差）显著低于对照组（n = 18），分别为1.2±0.7 l·h⁻¹和2.2±1.0 l·h⁻¹（p = 0.006）。肝病患者中各代谢产物的尿排泄均同等程度降低。根据Child Pugh评分、血清白蛋白和胆红素评估的肝病严重程度与安替比林清除率及代谢产物3-羟基甲基安替比林的尿排泄显著相关。肝炎活动指数（Knodell）仅与3-羟基甲基安替比林和4-羟基安替比林相关。
中重度慢性丙型肝炎似乎不会对安替比林的三种主要代谢途径产生不同程度的抑制。
